STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] PACS Group, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

PACS Group, Inc. director share purchase disclosed

A director of PACS Group, Inc. (PACS) reported buying common stock in an open-market transaction. On 11/24/2025, the reporting person purchased 16,724 shares of PACS common stock at a weighted average price of $29.897 per share, with individual trades executed between $29.59 and $30.16. After this transaction, the director beneficially owned 22,739 shares directly. The filing notes that detailed trade-by-trade pricing information within this range is available upon request.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dilsaver Evelyn S

(Last) (First) (Middle)
C/O PACS GROUP, INC.
262 N. UNIVERSITY AVE.

(Street)
FARMINGTON UT 84025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PACS Group, Inc. [ PACS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/24/2025 P 16,724 A $29.897(1) 22,739 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $29.59 to $30.16 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Remarks:
/s/ John Mitchell, Attorney-in-Fact 11/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PACS Group, Inc. (PACS) disclose?

A director of PACS Group, Inc. disclosed an open-market purchase of 16,724 shares of PACS common stock in a Form 4 filing.

On what date did the PACS director buy the shares reported on this Form 4?

The director’s purchase of PACS common stock occurred on 11/24/2025, which is listed as the transaction date and earliest transaction date.

At what price did the PACS director purchase the 16,724 shares?

The shares were bought at a weighted average price of $29.897 per share, with individual trades executed between $29.59 and $30.16 per share.

How many PACS shares does the director own after this transaction?

Following the reported purchase, the director beneficially owned 22,739 shares of PACS Group, Inc. common stock in direct ownership.

What type of security did the PACS director acquire on 11/24/2025?

The reporting person acquired common stock of PACS Group, Inc. as shown in Table I for non-derivative securities.

Were there any derivative securities reported by the PACS director on this Form 4?

Table II for derivative securities is included in the form layout but shows no derivative securities entries for this transaction.

How is the PACS directors ownership characterized in this Form 4?

The form identifies the reporting person as a Director of PACS Group, Inc., and the 22,739 shares reported are held with direct (D) ownership.

PACS Group

NYSE:PACS

PACS Rankings

PACS Latest News

PACS Latest SEC Filings

PACS Stock Data

5.04B
44.67M
72.29%
29.09%
1.67%
Medical Care Facilities
Services-skilled Nursing Care Facilities
Link
United States
FARMINGTON